Symposium "Pharmacoeconomic Factors Related to the Treatment of Schizophrenia". Chicago, IL, USA, 1998/04/08.
The assignment of costs in a cost-effectiveness analysis is a complex and disputed issue.
The Panel on Cost-Effectiveness in Health and Medicine was convened to discuss standards that could be applied across a range of areas of cost-effectiveness.
Additionally, the Panel had a mandate to resolve some controversial issues about the practice of cost-effectiveness that created difficulty in making comparisons across studies.
The Panel proposed these guidelines :
(1) Do at least some of the analysis from a social perspective ;
(2) Assign values to resources that reflect their opportunity costs ;
(3) Avoid zero counting of resources ;
(4) Avoid double counting of resources ;
(5) Make analyses only as exacting as necessary in a study.
Difficulties in data collection were discussed.
Among other questions considered by the panel were how to assign a value to the patient's time and which productivity costs to include in a cost-effectiveness analysis.
With tools and suggestions from the Panel on Cost-Effectiveness in Health and Medicine, the cost analyst can report costs accurately and provide accurate comparisons of cost performance across states, trial modalities, or diseases.
Mots-clés Pascal : Schizophrénie, Trouble psychiatrique, Chimiothérapie, Traitement, Neuroleptique, Psychotrope, Recommandation, Analyse coût efficacité, Analyse coût, Economie santé, Homme, Psychose
Mots-clés Pascal anglais : Schizophrenia, Mental disorder, Chemotherapy, Treatment, Neuroleptic, Psychotropic, Recommendation, Cost efficiency analysis, Cost analysis, Health economy, Human, Psychosis
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0189467
Code Inist : 002B02B03. Création : 16/11/1999.